Biohaven (BHVN) Projected to Post Earnings on Monday

Biohaven (NYSE:BHVN) is expected to release its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($1.22) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Biohaven Stock Performance

Shares of BHVN opened at $11.23 on Monday. The firm has a market capitalization of $1.19 billion, a P/E ratio of -1.48 and a beta of 1.14. Biohaven has a 52 week low of $7.48 and a 52 week high of $40.82. The stock has a 50 day moving average price of $11.52 and a two-hundred day moving average price of $12.84. The company has a debt-to-equity ratio of 1.91, a quick ratio of 2.86 and a current ratio of 2.86.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Morgan Stanley lowered their price target on Biohaven from $26.00 to $21.00 and set an “overweight” rating for the company in a research report on Tuesday, January 6th. JPMorgan Chase & Co. lowered their target price on shares of Biohaven from $47.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, November 20th. BTIG Research reiterated a “buy” rating and set a $16.00 price target on shares of Biohaven in a report on Tuesday, November 18th. Royal Bank Of Canada reduced their price objective on Biohaven from $19.00 to $9.00 and set a “sector perform” rating for the company in a research note on Thursday, November 6th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Biohaven in a research report on Wednesday, November 5th. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.40.

Hedge Funds Weigh In On Biohaven

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BHVN. PNC Financial Services Group Inc. increased its stake in shares of Biohaven by 113.7% in the third quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock worth $36,000 after purchasing an additional 1,268 shares in the last quarter. Arax Advisory Partners grew its stake in Biohaven by 943.3% in the 4th quarter. Arax Advisory Partners now owns 4,914 shares of the company’s stock valued at $55,000 after buying an additional 4,443 shares in the last quarter. Focus Partners Wealth purchased a new position in Biohaven in the 3rd quarter valued at approximately $87,000. Northwestern Mutual Wealth Management Co. raised its holdings in Biohaven by 145.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 9,152 shares of the company’s stock valued at $103,000 after acquiring an additional 5,417 shares during the period. Finally, Tower Research Capital LLC TRC lifted its position in shares of Biohaven by 198.6% during the second quarter. Tower Research Capital LLC TRC now owns 8,031 shares of the company’s stock worth $113,000 after acquiring an additional 5,341 shares in the last quarter. Institutional investors own 88.78% of the company’s stock.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.